Advertisement
Advertisement
U.S. markets closed
Advertisement
Advertisement
Advertisement
Advertisement

Metacrine, Inc. (MTCR)

NasdaqCM - NasdaqCM Real Time Price. Currency in USD
0.4290-0.0160 (-3.60%)
At close: 01:00PM EST
0.4110 -0.02 (-4.20%)
After hours: 03:59PM EST
Advertisement

Metacrine, Inc.

3985 Sorrento Valley Boulevard
Suite C
San Diego, CA 92121
United States
858 369 7800
https://www.metacrine.com

Sector(s)Healthcare
IndustryBiotechnology
Full Time Employees10

Key Executives

NameTitlePayExercisedYear Born
Dr. Preston S. Klassen M.D., M.H.S.Pres, CEO & Director749.38kN/A1969
Ms. Patricia MillicanChief Financial OfficerN/AN/A1973
Ms. Theresa LowryVP of HRN/AN/AN/A
Mr. Michael B. YorkChief Bus. OfficerN/AN/A1965
Amounts are as of December 31, 2021 and compensation values are for the last fiscal year ending on that date. Pay is salary, bonuses, etc. Exercised is the value of options exercised during the fiscal year. Currency in USD.

Description

Metacrine, Inc., a clinical-stage biopharmaceutical company, focuses on discovering and developing therapies for patients with gastrointestinal diseases. It is developing MET642, which has completed Phase I clinical trial for the treatment of ulcerative colitis. Metacrine, Inc. was incorporated in 2014 and is headquartered in San Diego, California.

Corporate Governance

Metacrine, Inc.’s ISS Governance QualityScore as of November 1, 2022 is 8. The pillar scores are Audit: 7; Board: 8; Shareholder Rights: 8; Compensation: 8.

Corporate governance scores courtesy of Institutional Shareholder Services (ISS). Scores indicate decile rank relative to index or region. A decile score of 1 indicates lower governance risk, while a 10 indicates higher governance risk.
Advertisement
Advertisement